Tatiana G. Antonova

ORCID: 0009-0007-6646-7454
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Language, Communication, and Linguistic Studies
  • Head and Neck Cancer Studies
  • Renal cell carcinoma treatment
  • Discourse Analysis and Cultural Communication
  • Language, Metaphor, and Cognition
  • Cancer Immunotherapy and Biomarkers
  • Healthcare cost, quality, practices
  • Cancer Genomics and Diagnostics
  • Voice and Speech Disorders
  • Salivary Gland Tumors Diagnosis and Treatment
  • Esophageal Cancer Research and Treatment
  • Cancer Diagnosis and Treatment
  • Economic and Financial Impacts of Cancer
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Bladder and Urothelial Cancer Treatments
  • Endometrial and Cervical Cancer Treatments
  • Renal and related cancers
  • Pancreatic and Hepatic Oncology Research
  • Lung Cancer Research Studies
  • European and Russian Geopolitical Military Strategies
  • Ovarian cancer diagnosis and treatment
  • Gastric Cancer Management and Outcomes
  • COVID-19 Clinical Research Studies
  • Cancer-related gene regulation
  • COVID-19 and healthcare impacts

City Clinical Hospital
2024-2025

City Hospital
2024-2025

Moscow City Oncology Hospital №62
2023

National Research Tomsk State University
2014

Aim. To evaluate the efficacy and safety of immune checkpoint inhibitors in patients with metastatic renal cell carcinoma (RCC) Russian patient population. Materials methods. This retrospective study included 231 (157 males 74 females) aged 44 to 86 years (median 64.56±8.09) who underwent examination treatment at Moscow City Hospital named after S.S. Yudin Center for Rehabilitation Treatment. Results. The median follow-up was 16.6 months (13.38-18.61). effectiveness therapy evaluated all...

10.26442/18151434.2025.1.203025 article EN Journal of Modern Oncology 2025-05-04

Введение. Стандартный режим индукционной химиотерапии по схеме DCF характеризуется высокой частотой объективного ответа у пациентов с распространенными опухолями головы и шеи. Высокая токсичность режима ограничивает возможность его применения. Проспективное нерандомизированное исследование оценивает эффективность безопасность иммунохимиотерапии (ИХТ) в качестве индукции. Цель. В этой работе представлены данные сравнения безопасности PF — пембролизумаб, а также риски отказа или незавершения...

10.37469/0507-3758-2024-70-6-1096-1105 article RU cc-by-nc-nd Voprosy Onkologii 2025-01-22

Background : Routine analysis of KRAS, NRAS, BRAF V600 mutations, as well MSI and HER2 guides treatment selection in colorectal cancer (CRC). Recent findings from the PRESSING PARADIGM trials have demonstrated that negative hyperselection patients based on results comprehensive genomic profiling better outcomes following anti-EGFR therapy. Study objective: The study aimed to retrospectively analyze occurrence alterations associated with potential resistance samples CRC treated Materials...

10.18027/2224-5057-2024-030 article EN cc-by Malignant tumours 2025-01-23

Treatment strategy of advanced unresectable head and neck squamous cell cancer (HNSCC) is limited to induction chemotherapy (ICT) followed by (chemo) radiotherapy (cRT) concurrent chemoradiotherapy (CCRT). However, the role ICT remains controversial considering lack overall survival benefit. The aim : evaluate in treatment locally HNSCC. Methods We performed a retrospective clinical study that included patients (pts) with stage III–IVa larynx, oropharynx hypopharynx. Results A total 176 pts...

10.18027/2224-5057-2024-021 article EN cc-by Malignant tumours 2025-01-22

Background. The approved regimen of induction chemotherapy with docetaxel + cisplatin 5-fluorouracil has high risk unacceptable toxicity for many patients advanced head and neck cancer (HNSCC). Toxicity can also compromise the delivery following chemoradiation. In order to improve results these pts treatment we conducted a prospective multicenter non-randomized phase II study immunochemotherapy followed by (chemo)radiation here report first objective response rate (ORR), safety profile...

10.26442/18151434.2024.4.203019 article EN Journal of Modern Oncology 2025-02-18

The combination of lenvatinib and pembrolizumab has emerged as the first non-chemo treatment for advanced endometrial cancer, particularly in cases refractory to standard therapies. This case describes efficacy safety a 62-year-old patient with endometrioid adenocarcinoma who received first-line therapy absence repair system deficiency after adjuvant therapy. offers potential extend survival patients mismatch proficient cancer have systemic neoadjuvant or

10.17650/1994-4098-2025-21-1-142-146 article EN cc-by Tumors of female reproductive system 2025-05-08

The article deals with the problem of metaphorical modeling social conflict in Russian media discourse. News and analytical texts newspapers news agencies, telling about Greece are analyzed. components metaphorically represented discourse sorted out studied. ways interpretation shaping its image within framework conceptual metaphors described.

10.1016/j.sbspro.2014.10.165 article EN Procedia - Social and Behavioral Sciences 2014-10-01

Aim. To compare of efficacy and safety combined immune therapy (dual immune-oncology – IO combination therapies, IO-IO) targeted (ITT) in the first line treatment patients with advanced renal cell carcinoma (RCC) treated real world clinical practice. Materials methods. The ambispective study enrolled metastatic RCC aged ≥18 years, measurable neoplastic lesions, who were first-line IO-IO or ITT. primary endpoint was progression-free survival (PFS). Results. included data from 126 [46 (36.5%)...

10.26442/18151434.2024.3.202888 article EN Journal of Modern Oncology 2024-11-11

10.17223/15617793/401/1 article EN Vestnik Tomskogo gosudarstvennogo universiteta 2015-12-01

Background. COVID-19 (COrona VIrus Disease 2019) is a serious threat to cancer patients, who are at an increased risk of severe infection complications. Pre-exposure prophylaxis with combination monoclonal antibodies, tixagevimab-cilgavimab (Evusheld), has been shown be effective in preventing COVID-19, reducing hospital admission rate and mortality immunocompromised individuals.
 Aim. To describe the experience using for pre-exposure Russian population patients solid tumors receiving...

10.26442/18151434.2023.3.202456 article EN Journal of Modern Oncology 2023-12-10

Background. Combination therapy is the standard of care for intermediate and poor prognosis metastatic renal cell carcinoma. In IMDC prognostic classification, tumor stage histological type are not considered due to lack independent impact on overall survival. The CLEAR study demonstrated efficacy lenvatinib pembrolizumab combination in long-term treatment outcomes, including survival compared sunitinib. KEYNOTE-B61 high this patients with non-clear Aim. To evaluate burden histotypes....

10.26442/18151434.2024.3.202977 article EN Journal of Modern Oncology 2024-11-11
Coming Soon ...